Section Arrow
TARS.NASDAQ
- Tarsus Pharmaceuticals
Quotes are at least 15-min delayed:2026/01/06 22:49 EST
Regular Hours
Last
 79.88
+0.13 (+0.16%)
Day High 
82.31 
Prev. Close
79.75 
1-M High
85.25 
Volume 
433.46K 
Bid
76.8
Ask
82
Day Low
78.8 
Open
79.91 
1-M Low
76.34 
Market Cap 
3.39B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 81.65 
20-SMA 80.92 
50-SMA 76.76 
52-W High 85.25 
52-W Low 38.51 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.99/2.90
Enterprise Value
3.46B
Balance Sheet
Book Value Per Share
7.89
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
182.95M
Operating Revenue Per Share
0.29
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CYCNCyclerion Therapeutics1.95+0.57+41.30%-- 
ALMSAlumis Inc.16.23+7.92+95.31%0.33PE
MREOMereo BioPharma Group plc0.379-0.1016-21.14%-- 
SLSSELLAS Life Sciences Group4.1-0.9-18.00%-- 
RXRXRecursion Pharmaceuticals4.55+0.18+4.12%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.